Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial
Titel:
Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial
Auteur:
Mateos, María-Victoria Paiva, Bruno Cedena, M Teresa Puig, Noemí Sureda-Balari, Ana Maria de la Calle, Verónica Gonzalez Oriol, Albert Ocio, Enrique M Rosiñol, Laura Montes, Yolanda González Bargay, Joan García, María Esther González Lakhwani, Sunil Payer, Angel Ramirez Suarez-Cabrera, Alexia Blanchard, María-Jesús Garzón, Sebastián Montero, Felipe Casado Cabañas, Valentín de Oteyza, Jaime Pérez Gironella, Mercedes Martinez-Lopez, Joaquín Casasús, Ana Isabel Teruel Delgado-Beltrán, María Pilar Prieto, Elena Lahuerta, Juan José Bladé, Joan San-Miguel, Jesús